TABLE 3.
Model predicted PASI75 response of treatments at different time points.
| Drug | Regimen | PASI75(%) a | ||||
|---|---|---|---|---|---|---|
| Week 4 | Week 8 | Week 12 | Week 16 | Week 24 | ||
| TNF-α inhibitor | ||||||
| Adalimumab | 80 mg 0 40 mg 1, q2w | 21.30 (8.59, 39.20) | 56.95 (36.30, 70.40) | 67.80 (53.70, 77.30) | 71.20 (61.31, 79.90) | 72.80 (65.20, 80.10) |
| Infliximab | 5 mg/kg 0, 2, 6, q8w | 34.10 (16.60, 55.20) | 67.10 (47.70, 80.20) | 75.65 (62.80, 84.00) | 78.20 (69.40, 85.40) | 79.70 (72.71, 86.40) |
| Etanercept | 50 mg biw | 7.98 (2.29, 17.90) | 34.40 (18.70, 48.80) | 49.60 (34.91, 60.20) | 55.00 (43.50, 64.40) | 57.80 (48.30, 66.70) |
| Certolizumab pegol | 400 mg 0, 2, 4 200 mg q2w | 15.30 (5.30, 31.20) | 53.15 (33.72, 68.60) | 67.70 (52.61, 77.69) | 71.80 (62.01, 80.40) | 74.00 (67.00, 81.30) |
| IL-12/23 inhibitor | ||||||
| Ustekinumab | 45 mg 0, 4, q12w | 10.75 (3.36, 23.70) | 47.30 (28.10, 61.90) | 65.30 (50.90, 75.80) | 71.20 (61.30, 80.70) | 74.50 (66.60, 81.90) |
| Briakinumab | 100 mg q4w | 21.50 (8.78, 41.70) | 66.80 (46.91, 80.20) | 79.50 (67.81, 87.70) | 82.80 (74.60, 90.10) | 84.40 (77.80, 91.10) |
| IL-23 inhibitor | ||||||
| Guselkumab | 100 mg 0, 4, q8w | 20.65 (8.40, 38.19) | 67.00 (47.21, 79.70) | 80.40 (69.00, 88.30) | 83.90 (76.30, 90.40) | 85.80 (79.40, 92.20) |
| Tildrakizumab | 100 mg 0, 4, q12w | 9.26 (2.33, 21.40) | 42.80 (22.70, 57.70) | 61.00 (44.71, 71.60) | 68.10 (56.90, 76.20) | 71.20 (62.60, 79.40) |
| Risankizumab | 150 mg 0, 4, q12w | 21.15 (8.78, 40.10) | 72.50 (53.31, 83.90) | 85.95 (75.71, 92.60) | 89.40 (82.90, 94.70) | 91.00 (85.90, 96.00) |
| IL-17 inhibitor | ||||||
| Secukinumab | 300 mg 0, 1, 2, 3, 4, q4w | 39.60 (20.00, 62.60) | 77.20 (58.90, 87.50) | 84.50 (75.70.91.70) | 86.70 (79.40, 93.10) | 87.60 (82.20, 93.60) |
| Ixekizumab | 160 mg 0, q4w | 56.50 (33.50, 76.60) | 80.40 (62.80, 89.40) | 85.90 (76.12, 92.79) | 87.70 (80.50, 93.10) | 88.50 (82.50, 93.90) |
| Ixekizumab | 160 mg 0 80 mg q4w | 48.95 (26.90, 70.39) | 75.20 (56.50, 85.80) | 82.40 (69.50, 89.80) | 84.60 (77.10, 90.90) | 85.70 (79.90, 91.50) |
| Brodalumab | 210 mg 0, 1, 2, q2w | 48.55 (27.20, 70.50) | 74.95 (56.60, 85.50) | 81.70 (71.70, 89.50) | 84.00 (76.30, 90.10) | 85.20 (79.10, 91.30) |
| PDE4 inhibitor | ||||||
| Apremilast | 30 mg b.i.d. | 5.68 (0.92, 13.40) | 20.30 (9.18, 32.69) | 29.50 (17.50, 39.79) | 33.20 (23.30, 41.70) | 35.30 (27.31, 43.50) |
| JAK inhibitor | ||||||
| Tofacitinib | 5 mg b.i.d. | 9.07 (2.48, 19.90) | 29.00 (14.40, 42.40) | 39.20 (25.90, 50.50) | 42.80 (32.30, 51.60) | 45.10 (36.30, 53.90) |
| Tofacitinib | 10 mg b.i.d. | 16.30 (5.52, 32.50) | 46.55 (26.50, 62.00) | 57.70 (41.90, 68.00) | 61.60 (51.00, 70.20) | 63.10 (54.41, 72.30) |
| Baricitinib | 10 mg qd | 7.34 (1.66, 16.60) | 33.10 (17.10, 46.30) | 48.70 (34.40, 59.50) | 54.80 (44.10, 64.10) | 58.30 (49.91, 67.10) |
| CD2 antagonist | ||||||
| Alefacept | 10 mg qw | 1.90 (0, 5.85) | 7.46 (1.83, 14.50) | 12.90 (5.90, 19.60) | 15.90 (9.40, 23.20) | 19.30 (12.60, 26.20) |
| Dihydrofolate reductase inhibitor | ||||||
| Methotrexate | 20 mg qw | 4.14 (0.48, 10.50) | 19.00 (7.61, 30.30) | 30.80 (18.51, 42.10) | 36.80 (25.80, 46.30) | 40.10 (31.80, 48.30) |
PASI, Psoriasis Area and Severity Index score; PASI75, ≥75% reduction from baseline Psoriasis Area and Severity Index score; TNF, tumor necrosis factor; IL, interleukin; PDE, phosphodiesterase; JAK, Janus kinase; NA, not available; s.c., subcutaneous; p. o., oral; qw, once weekly; q2w, once every 2 weeks; q4w, once every 4 weeks; q8w, once every 8 weeks; q12w, once every 12 weeks; biw, twice weekly; qd, once daily.
a
Data are shown as median (95% CI).